Why Patients Switch Between These Weight Loss Treatments
Understanding Mounjaro vs Wegovy Dosage Differences for Switching
The key difference when considering Mounjaro vs Wegovy dosage lies in their mechanisms of action. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, while Wegovy (semaglutide) targets GLP-1 receptors exclusively. This fundamental difference means direct dose-to-dose conversion isn't straightforward—your prescriber will assess your current response, side effect profile, and treatment goals. Mounjaro's dosing starts at 2.5mg weekly, escalating to a maximum of 15mg, whilst Wegovy begins at 0.25mg and reaches 2.4mg maintenance dose. Both medications require careful dose escalation over 16-20 weeks to minimise gastrointestinal side effects and optimise tolerability.
When switching between these medications, your clinical history with the current treatment heavily influences the starting dose decision. Patients switching from higher Mounjaro doses don't necessarily require Wegovy's maximum 2.4mg dose, as the medications work differently. Your EverydayMeds prescriber will review your weight loss progress, side effect experience, and individual factors to determine the most appropriate Wegovy starting point. This personalised approach ensures continuity of treatment benefits whilst minimising the risk of adverse effects during transition.
Wegovy vs Mounjaro Dosage: Cost Comparison and Savings Potential
Switching between Mounjaro vs Wegovy dosage options can offer significant cost advantages depending on your maintenance dose requirements. Wegovy's 0.25mg starter pens cost £79.99, with the maintenance 2.4mg dose at £209.99 per pen after applying discount codes at checkout. New customers benefit from code FIRST40, whilst returning patients use DOSE25 to access these competitive prices. Our bundle options provide additional convenience, such as the Progress Duo (0.5mg & 1mg) at £189.99, perfect for patients transitioning from other GLP-1 medications.
The cost-effectiveness of switching depends on your current Mounjaro dose and treatment response patterns. Many patients find Wegovy's pricing structure more predictable, especially when reaching maintenance therapy. Our 3-pen bundles, like the Ultimate Stability Trio (2.4mg ×3) at £649.99, ensure uninterrupted supply for patients who've successfully switched and achieved stable weight management. EverydayMeds stocks both medications, allowing seamless transitions without changing pharmacy providers—this continuity ensures consistent cold-chain handling and reliable supply management.
Clinical Evidence Supporting Mounjaro vs Wegovy Dosage Decisions
The STEP trial programme, particularly findings published by Wilding et al. in NEJM 2021, demonstrates Wegovy's efficacy across its dosing range in clinical trials. Patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. These results support the structured dose escalation protocol from 0.25mg through to 2.4mg maintenance dosing. The STEP 2 trial showed sustained efficacy in patients with type 2 diabetes, achieving approximately 9.6% weight reduction.
When comparing Mounjaro vs Wegovy dosage effectiveness, both medications have demonstrated significant weight management benefits in their respective clinical programmes. However, direct head-to-head comparisons aren't available due to different trial designs and patient populations. Your prescriber will consider your individual response patterns, medical history, and treatment goals when recommending dosage adjustments during any medication switch.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones that regulate blood sugar and appetite. Unlike Mounjaro's dual-action approach, Wegovy specifically targets GLP-1 receptors in the brain's appetite control centres, promoting feelings of fullness and reducing food cravings. This mechanism explains why the Wegovy dosage escalation protocol is crucial—starting at 0.25mg allows your body to adapt to enhanced satiety signals gradually. The medication works by slowing gastric emptying, which extends the feeling of fullness after meals and may help reduce portion sizes naturally. Each weekly injection maintains steady medication levels, supporting consistent appetite regulation throughout your weight management journey alongside a reduced-calorie diet and increased physical activity.
Seamless Ordering Process for Mounjaro vs Wegovy Dosage Switches
Switching between Mounjaro vs Wegovy dosage regimens through EverydayMeds involves a streamlined clinical assessment process designed for medication transitions. Our 3-minute online assessment captures your current treatment history, including your present dose, duration of therapy, weight loss achieved, and any side effects experienced. This information enables our prescribers to make informed decisions about appropriate Wegovy starting doses when switching from Mounjaro. Standard prescriber review takes 3 working days, with express 24-hour options available for urgent switches due to supply issues or treatment interruptions. Once approved, your new Wegovy prescription ships via next-day delivery using temperature-controlled cold-chain logistics, ensuring medication integrity and treatment continuity.
Storage Advantages When Switching Wegovy vs Mounjaro Dosage
Wegovy offers practical storage benefits that many patients appreciate when switching from Mounjaro, particularly regarding room temperature stability. Whilst both medications require refrigeration at 2-8°C before first use, Wegovy FlexTouch pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration—significantly longer than Mounjaro's 21-day room temperature limit. This extended stability makes Wegovy more travel-friendly and reduces anxiety about accidental temperature exposure. The FlexTouch pen design provides clear dose confirmation and smooth injection experience, with each pen containing four doses for weekly administration. Dose escalation follows a mandatory schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg for maintenance from week 17 onwards.
Strategic Switching: Optimising Your Mounjaro vs Wegovy Dosage Transition
The decision to switch between Mounjaro vs Wegovy dosage regimens often stems from personalised treatment optimisation rather than treatment failure. Many patients switch due to insurance coverage changes, supply availability, side effect profiles, or cost considerations. Some individuals find Wegovy's GLP-1-only mechanism provides adequate appetite control with fewer gastrointestinal side effects compared to dual-receptor medications. The transition timing is crucial—switching during stable weight loss phases rather than active dose escalation periods typically yields better outcomes.
Your EverydayMeds prescriber will coordinate the switch timing to minimise treatment gaps and maintain therapeutic momentum. This might involve starting Wegovy at a higher dose if you've demonstrated good tolerability on Mounjaro, or beginning more conservatively if you've experienced side effects. The goal is maintaining your weight management progress whilst potentially improving treatment satisfaction, cost-effectiveness, or convenience factors that matter most to your long-term adherence.
Complete Your Mounjaro vs Wegovy Dosage Switch Today
Ready to explore switching between Mounjaro vs Wegovy dosage options with potential cost savings and storage advantages? EverydayMeds makes the transition straightforward with expert clinical oversight and competitive pricing from £79.99 per pen. New customers can apply code FIRST40 at checkout, whilst returning patients benefit from DOSE25 discounts on all Wegovy doses. Our comprehensive bundle options, including the convenient Progress Duo and Ultimate Stability Trio, support both initial switches and long-term maintenance therapy. Start your clinical assessment today at our weight loss collection, where our GPhC-registered prescribers (#9012878) will guide your personalised switching strategy. Both Wegovy and Mounjaro remain available from EverydayMeds—your prescriber can help determine which prescription-only medicine best supports your individual weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
